Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy(TM) Human Clinical Trial

Stock Information for First Wave BioPharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About First Wave BioPharma Inc.

Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA
Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic
Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy(TM)
Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025
Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy(TM)
Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans
Vivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.